Navigation Links
Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research

ymptoms. Santaris Pharma holds the world wide patent rights to the exploitation of LNA in pharmaceuticals and presently has three drugs in preclinical or clinical development. The lead drug candidate, SPC2996, is currently undergoing international, multicenter, phase I/II clinical studies in Chronic Lymphocytic Leukaemia.

For further company information see www.santaris.com <http://www.santaris.com/>

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of and future demand for Santaris products and the impact of competitive products and pricing. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Santaris does not intend to update this information.

Best regards

Annabel Entress Account Manager --------------------------------------------- Direct line: +44 (0)20 7268 3234

Main tel: +44 (0)20 7268 3002 Fax: +44 (0)20 7268 3102

Please note our new contact details:

85 Totte
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:12/24/2014)... 2014  Actavis plc (NYSE: ACT ... a complete response letter from the U.S. Food ... Application (NDA) for the fixed-dose combination (FDC) of ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... receipt of a complete response letter, Actavis remains ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... WATERTOWN, Mass., Oct. 17 EnVivo ... developing drugs for,neurodegenerative diseases, today announced ... Alzheimer,s, Schizophrenia and Huntington,s,diseases. EnVivo ... orally,active Alpha 7 Nicotinic Acetylcholine Receptor ...
... ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 A ... Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the French,maritime ... leads to an increase in blood flow and oxygen supply,to muscles. ...
Cached Medicine Technology:EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3
(Date:12/25/2014)... (PRWEB) December 25, 2014 BambooFlooringChina.com sells ... high quality bamboo flooring. Today, the company announces ... in many styles and colors. , BambooFlooringChina.com is the ... CEO, the promotion is valid until Jan. 20, 2015. ... strips and woven with a natural thread. All the ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... illnesses can receive effective, less expensive care from a clinic ... a team of dedicated health care professionals, a new study ... and need either hospitalization or a trip to the emergency ... clinic at the University of Texas in Houston versus usual ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
Breaking Medicine News(10 mins):Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... for about half of all visits to psychotherapists, and ... with couples.// The therapist helps the couple work on ... perpetuate conflict, explains the March 2007 issue of the ... make little use of psychiatric diagnosis, but they do ...
... of breastfeeding outweigh the risks of virus transmission from HIV-positive ... African nations.// ,A study in Zambia showed ... breast milk ¯ beyond a set time period of ... The study was a collaboration between US universities and University ...
... shows that a form of vitamin A used to treat ... small molecules called microRNAs (miRNAs) in the// leukemic cells. ... miRNAs inhibit the action of two genes important for cancer ... ,The drug is called all-trans-retinoic acid (ATRA) and it ...
... of bioactive compounds in the blood and boost antioxidant ... start// to rival the juice for boosting health. ... rise, particularly in the UK where sales have rocketed ... the antioxidant-rich fruit that has commonly been linked to ...
... in Porirua is not linked to a cluster of cases ... have been treated for typhoid in Porirua and those cases ... of health, regional public health, Wellington, said last night. ... which was being treated very seriously. ,Two of ...
... According to a study published on bmj.com, the second born ... This study also states that there is no big// difference ... second twin born at or after the complete term of ... shortly after birth. ,Many studies have talked about ...
Cached Medicine News:Health News:Breastfeeding Benefits may Outweigh HIV Risk 2Health News:Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down 2Health News:Science Builds Behind Pomegranate Extracts for Health 2
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
... EX accelerators are true ... Varian multileaf collimation and ... which enable you to ... computer-driven IMRT treatments, as ...
The Clinac 2300 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
... reliable system. Varian accelerators offers highest ... fastest beam-on times to full stability ... milliseconds, pulse-to-pulse beam control for dynamic ... of multileaf collimator (MLC) products that ...
Medicine Products: